Condition 1: renal failure. Condition 2: CMV infection. Acute renal failure Other and unspecified infectious diseases
Conditions
Interventions
Intervention 1: control group: treatment with Valganciclovir, 10-15 mg per kg for everyone, daily, for 3 months. Intervention 2: intervention group: treatment with valganciclovir, 10-15 mg per kg for
Treatment - Drugs
control group: treatment with Valganciclovir, 10-15 mg per kg for everyone, daily, for 3 months
intervention group: treatment with valganciclovir, 10-15 mg per kg for everyone, daily, for 6 months
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
1 Years to 14 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: The children who receive organs from people who are CMV positive; The children are 1-14 years-old Exclusion criteria: The use of Thymoglobuline drug; The children who are effected severely by side effects of valganciclovir drug; for example: severe leukopenia or anemia
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CMV infection. Timepoint: before intervention, 15 days after intervention, every month until 1 year after intervention. Method of measurement: Laboratory methods of Qualitit PCR and PP65. | — |
Secondary
| Measure | Time frame |
|---|---|
| Side effects of valganciclovir drug like: Anemia and Allergic hypersensitivity. Timepoint: every month after intervention until 1 year. Method of measurement: clinical presentation. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactNiloofar Khosravi
Ali-Asghar Hospital
Outcome results
None listed